All news

Bayer lifts 2026 EBITDA guide to EUR 9.8-10.3 billion after Q3 beat; shares up 2.7%

Newsquawk · · AI-summarised by FinFlash

Bayer posted third-quarter sales of EUR 10.05 billion against EUR 9.98 billion expected, while adjusted EBITDA reached EUR 1.62 billion, well above the EUR 1.42 billion forecast. The German pharma and crop science group raised its full-year adjusted EBITDA guidance to EUR 9.8 billion to EUR 10.3 billion, from a prior range of EUR 9.6 billion to EUR 10.1 billion. The shares rose 2.7% in early European indications.

So What?

A clean beat and raise supports European healthcare and chemicals sentiment. Watch whether the upgrade holds through the rest of the DAX reporting season.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.